Plasma Concentration of Biological Markers in Placenta Accreta Spectrum

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

19 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-08-30

Study Completion Date

2023-07-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this exploratory study is to determine how well maternal serum biomarkers and placental micro-particles (MP) correlate with placenta accreta spectrum (PAS) at the time of cesarean delivery in women with suspected PAS compared to women without PAS. Our aim is to determine if women with PAS have a unique MP and protein signature at the time of delivery compared with women without PAS.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Plasma Concentration of Biological Markers in Placental Abruption

NCT03782168

Abruptio Placentae

TERMINATED

A Serum Galectin-3 Levels in Placenta Accreta Spectrum Pregnancies

NCT05945446

Placenta Accreta, Third Trimester

COMPLETED

Placental Growth and Adverse Pregnancy Outcomes

NCT01669525

Hypertension Induced by Pregnancy Pre-Eclampsia IUGR

COMPLETED

Study of Placental Function in Healthy and Pathological Pregnancies

NCT02321007

Pregnancy

RECRUITING

Screening for Intrapartum Fetal Compromise Using Placental Biomarkers

NCT07258329

Pregnant Women

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Maternal blood samples will be taken at various points during the intrapartum period. A healthy group of women admitted for delivery will act as a matched control and will have their blood sampled at similar time points. The primary outcome variables will include the total number of micro-particles, the number of micro-particles from each cell line (platelet, placental, endothelial etc.), and protein markers The knowledge gained from this study has the potential to develop a diagnostic test for PAS with the ability to improve management and outcomes for mother and baby through earlier diagnosis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Placenta Accreta Placenta Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placenta accreta spectrum

Mother-infant dyads with suspected or confirmed diagnosis of placenta accreta spectrum

There is no other intervention, only clinical treatment.

Intervention Type OTHER

There is no other intervention, only clinical treatment

Phenotypically-matched controlled group

Mother-infant dyads admitted for delivery without placenta accreta spectrum

There is no other intervention, only clinical treatment.

Intervention Type OTHER

There is no other intervention, only clinical treatment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

There is no other intervention, only clinical treatment.

There is no other intervention, only clinical treatment

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 - to 45-years old, inclusive
* Suspected or confirmed PAS or phenotypically matched controls
* Delivery by cesarean section
* Gestational age greater than 28 weeks
* Singleton pregnancy